Jeff Ludwig - Chief Commercial Officer - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (nerati
Susan Malecha - Senior Director, Medical Affairs - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Cana
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Inc (PBYI) Stock: Do Analysts Think You Should Sell?
PHOTO TAKEN 17AUG05- A puma named Zonko swims in the Chimore River near Machia Park in Villa Tunari in the Bolivian Amazon jungle, 520 km (323 miles) southeast of La Paz, August
Puma Biotechnology, Inc. - Research - Overview, Competitors, and Employees | Apollo.io
Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR) - Insider Monkey
APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio - TheStreet
Puma Biotech (PBYI) Hoping for a Bounce at Annual Meeting of Cancer Society - TheStreet
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Focus Areas - Department of Molecular Pharmacology and Experimental Therapeutics Research - Mayo Clinic Research
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells - ScienceDirect
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Sponsored Research: Mirati Therapeutics, Inc; Boehringer-Ingelheim; Eli Lilly and Company; Takeda Oncology; Puma Biotechnology; Astellas Pharmaceuticals; AstraZeneca; Daiichi Sankyo; Revolution Medicines Consulting Fees: Mirati Therapeutics, Inc; Boe ...
Sponsored Research: Mirati Therapeutics, Inc; Boehringer-Ingelheim; Eli Lilly and Company; Takeda Oncology; Puma Biotechnology; Astellas Pharmaceuticals; AstraZeneca; Daiichi Sankyo; Revolution Medicines Consulting Fees: Mirati Therapeutics, Inc; Boe ...
Puma Biotechnology
Takeda offloads cancer drug to Puma
Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (
